Recent Comments

Comment RSS

Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Study reveals effectiveness of radiation therapy in achieving local control and palliation in patients with PNTs

20. November 2009 11:10
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO). [More]

RaySearch Laboratories' interim report for the period January 1 – September 30, 2009

20. November 2009 04:16
“It is extremely satisfying that the major development efforts during recent years are now beginning to pay off. In November our new product for Philips started generating revenues and we anticipate that the total revenue contribution from this and other new products will exceed SEK 10 M already in the fourth quarter,” says Johan Löf, President of RaySearch. [More]

Posted in: Business / Finance

Tags: ,

US and European market for radiopharmaceuticals continues to gain momentum

20. November 2009 02:41
Research and Markets (http://www.researchandmarkets.com/research/410c60/radiopharmaceutica) has announced the addition of the "Radiopharmaceuticals - A US and European Market Analysis" report to their offering. [More]

Comprehensive report on world cancer therapies market

20. November 2009 01:37
Research and Markets (http://www.researchandmarkets.com/research/4b82d8/cancer_therapies) has announced the addition of the "Cancer Therapies - Global Market Opportunities" report to their offering. [More]

iCAD and AdMeTech Foundation sign a strategic partnership agreement

19. November 2009 01:49
iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a strategic partnership with the AdMeTech Foundation, a non-profit organization with a mission to end prostate cancer as a patient care crisis and socio-economic problem. [More]

Radiation breakthrough to treat breast cancer patients in one day arrives at CTCA

19. November 2009 01:34
A radiation breakthrough to treat breast cancer patients in one day, as opposed to the current average of six weeks, has arrived at Cancer Treatment Centers of America(R) (CTCA) in Philadelphia. CTCA will become the first in the country to offer this treatment option using the Novac7 technology from Rome, Italy. [More]

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

18. November 2009 23:55
BSD Medical Corporation (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , ,

Study to test anti-tumor effects of AEOL 10150 initiated

18. November 2009 03:04
Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts. [More]

New insights into cells' reaction to DNA damage

17. November 2009 04:55
Cancer researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have gained new insights into how cells react to DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit have shown that the protein PARP-1, which detects DNA damage within seconds, activates the transcription factor NF-kappaB, a well-known regulator of gene expression. [More]

Posted in: Medical Science News

Tags: , , , , , , ,

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

13. November 2009 10:56
Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009. [More]

3-D software uses real patient data; offers virtual reality technology for doctors and students

12. November 2009 00:06
James Oliver picked up an Xbox game controller, looked up to a video screen and used the device's buttons and joystick to fly through a patient's chest cavity for an up-close look at the bottom of the heart. [More]

Posted in: Device / Technology News

Tags: , ,

Men more likely to abandon partners diagnosed with cancer

11. November 2009 04:31
A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact. [More]

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

11. November 2009 01:51
Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures. [More]

SAVI reaches a major milestone in breast brachytherapy

10. November 2009 05:08
This month marks three years since physicians began offering SAVI™ radiation treatment as part of breast conservation therapy for early-stage breast cancer – a major milestone in breast brachytherapy. [More]

Posted in: Device / Technology News | Women's Health News

Tags: , , ,

St. Jude collaborates with UF Proton Therapy Institute to commence proton therapy clinical study

10. November 2009 03:38
St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.